Scroll

mupirocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1857	12650-69-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mupirocin mupricin pseudomonic acid turixin mupirocin calcium bactroban BRL 4910A	A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. Molecular weight: 500.63 Formula: C26H44O9 CLOGP: 1.54 LIPINSKI: 1 HAC: 9 HDO: 4 TPSA: 146.05 ALOGS: -4.28 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mupirocin
mupricin
pseudomonic acid
turixin
mupirocin calcium
bactroban
BRL 4910A

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Molecular weight: 500.63
Formula: C26H44O9
CLOGP: 1.54
LIPINSKI: 1
HAC: 9
HDO: 4
TPSA: 146.05
ALOGS: -4.28
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1987	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	741.99	14.84	226	9301	18682	56263858
Chronic sinusitis	95.08	14.84	40	9487	8338	56274202
Drug ineffective	63.48	14.84	314	9213	918675	55363865
Procedural pain	56.79	14.84	35	9492	16236	56266304
Paraesthesia oral	55.37	14.84	33	9494	14416	56268124
Hyperchlorhydria	41.39	14.84	14	9513	1601	56280939
Dyspepsia	39.57	14.84	59	9468	83412	56199128
Therapeutic product effect incomplete	38.02	14.84	66	9461	105965	56176575
Nasal vestibulitis	37.31	14.84	6	9521	20	56282520
Folate deficiency	33.70	14.84	13	9514	2164	56280376
Purpura senile	32.59	14.84	9	9518	520	56282020
Staphylococcal infection	31.06	14.84	35	9492	37583	56244957
Product dose omission issue	30.71	14.84	90	9437	204663	56077877
Tarsal tunnel syndrome	27.89	14.84	8	9519	531	56282009
Toxicity to various agents	27.45	14.84	3	9524	224561	56057979
Weight decreased	27.19	14.84	96	9431	240618	56041922
Hospitalisation	24.70	14.84	45	9482	74955	56207585
Odynophagia	24.64	14.84	15	9512	6803	56275737
Therapy interrupted	23.15	14.84	25	9502	25600	56256940
Resorption bone increased	21.28	14.84	8	9519	1242	56281298
Vestibular disorder	20.82	14.84	8	9519	1317	56281223
Cellulitis	18.66	14.84	40	9487	74909	56207631
Bronchial oedema	17.92	14.84	4	9523	95	56282445
Impetigo	17.72	14.84	7	9520	1241	56281299
Sinusitis	16.74	14.84	72	9455	197509	56085031
Pyrexia	15.83	14.84	123	9404	418650	55863890
Skin infection	15.81	14.84	15	9512	13180	56269360
Vertigo positional	15.56	14.84	8	9519	2621	56279919
General physical health deterioration	15.05	14.84	5	9522	170005	56112535

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nasal vestibulitis	52.45	18.06	8	4909	19	31692408
Food aversion	42.20	18.06	10	4907	341	31692086
Dermatitis atopic	36.74	18.06	17	4900	4845	31687582
Staphylococcal infection	31.96	18.06	31	4886	30601	31661826
Toxic epidermal necrolysis	30.85	18.06	25	4892	19499	31672928
Burkholderia test positive	27.52	18.06	9	4908	1013	31691414
Pain of skin	26.80	18.06	13	4904	4113	31688314
Skin discolouration	21.87	18.06	19	4898	16288	31676139
Cheilitis	20.93	18.06	9	4908	2159	31690268
Product dose omission issue	20.09	18.06	48	4869	105538	31586889
Hypophagia	18.77	18.06	20	4897	22022	31670405
Product use in unapproved indication	18.77	18.06	45	4872	99126	31593301
Pruritus	18.75	18.06	52	4865	125115	31567312

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	76.43	14.23	33	11702	7495	70909214
Chronic sinusitis	75.94	14.23	34	11701	8417	70908292
Procedural pain	61.77	14.23	38	11697	17971	70898738
Paraesthesia oral	49.01	14.23	31	11704	15386	70901323
Hyperchlorhydria	36.08	14.23	13	11722	1833	70914876
Dyspepsia	34.92	14.23	57	11678	89020	70827689
Food aversion	33.78	14.23	10	11725	759	70915950
Product dose omission issue	33.37	14.23	95	11640	217373	70699336
Weight decreased	31.69	14.23	118	11617	310370	70606339
Toxicity to various agents	31.40	14.23	12	11723	382160	70534549
Therapeutic product effect incomplete	29.72	14.23	63	11672	119819	70796890
Tarsal tunnel syndrome	28.58	14.23	8	11727	497	70916212
Purpura senile	28.49	14.23	8	11727	503	70916206
Cellulitis	28.09	14.23	55	11680	98873	70817836
Folate deficiency	26.61	14.23	12	11723	3018	70913691
Dermatitis atopic	25.88	14.23	17	11718	8990	70907719
Resorption bone increased	24.27	14.23	9	11726	1376	70915333
Pain of skin	23.87	14.23	17	11718	10249	70906460
Odynophagia	21.72	14.23	16	11719	10159	70906550
Staphylococcal infection	20.68	14.23	34	11701	53370	70863339
Skin discolouration	20.52	14.23	28	11707	37297	70879412
Toxic epidermal necrolysis	19.26	14.23	28	11707	39529	70877180
Skin infection	19.05	14.23	18	11717	16094	70900615
Surgery	18.81	14.23	24	11711	29965	70886744
Pneumonia	18.71	14.23	165	11570	596067	70320642
Bronchial oedema	18.22	14.23	4	11731	90	70916619
Knee operation	18.20	14.23	11	11724	5036	70911673
Steroid withdrawal syndrome	17.65	14.23	6	11729	713	70915996
Skin exfoliation	17.55	14.23	30	11705	48596	70868113
Therapy interrupted	17.40	14.23	21	11714	24781	70891928
Drug interaction	16.96	14.23	23	11712	381418	70535291
Vestibular disorder	16.68	14.23	8	11727	2312	70914397
Skin cancer	15.77	14.23	15	11720	13521	70903188
Dry skin	15.75	14.23	31	11704	55900	70860809
Dermatitis contact	15.75	14.23	13	11722	9736	70906973
Otitis externa fungal	14.81	14.23	3	11732	45	70916664
Vertigo positional	14.66	14.23	8	11727	3025	70913684

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D06AX09	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use
ATC	R01AX06	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Other nasal preparations
FDA EPC	N0000175515	RNA Synthetase Inhibitor Antibacterial
FDA MoA	N0000175516	RNA Synthetase Inhibitors
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:48001	protein synthesis inhibitors
CHEBI has role	CHEBI:35441	antiinfective agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Impetigo	indication	48277006	DOID:8504
Staph Aureus Traumatic Skin Lesion Infection	indication
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization	indication
Traumatic Skin Lesion Streptococcus Pyogenes Infection	indication
Folliculitis	off-label use	13600006	DOID:4409
Atopic dermatitis	off-label use	24079001	DOID:3310
Eczema	off-label use	43116000
Epidermolysis bullosa	off-label use	61003004	DOID:2730
Ecthyma	off-label use	85791004
Furunculosis	off-label use	112650006
Minor Bacterial Skin Infections	off-label use
Skin irritation	contraindication	367466007

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Bacterial infections of the skin caused by strains of Staphylococcus aureus	Indication
Dogs	Bacterial infections of the skin caused by Staphylococcus intermedius	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Bactoderm Ointment	Zoetis Inc.	1
Muricin	Fougera Pharmaceuticals Inc.	1
Mupirocin Ointment USP, 2%	Taro Pharmaceuticals U.S.A. Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.76	acidic
pKa2	12.42	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 2% BASE	MUPIROCIN	ALEOR DERMACEUTICALS	A213053	Nov. 16, 2021	RX	CREAM	TOPICAL	June 27, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Isoleucine--tRNA ligase, cytoplasmic	Enzyme	P41252	SYIC_HUMAN		IC50	9.10	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI1_STAAU	INHIBITOR			DRUGBANK	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_STRP1	INHIBITOR			CHEMBL	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_ECOLI		Ki	8.60	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_THET8		Ki	7.22	CHEMBL
Isoleucine--tRNA ligase, putative, EC 6.1.1.5	Unclassified		Q8I5G6_PLAF7		IC50	7.24	IUPHAR

External reference:

ID	Source
4019345	VUID
N0000147519	NUI
D01076	KEGG_DRUG
115074-43-6	SECONDARY_CAS_RN
4019345	VANDF
4021018	VANDF
C0085259	UMLSCUI
CHEBI:7025	CHEBI
MRC	PDB_CHEM_ID
CHEMBL3989715	ChEMBL_ID
CHEMBL2068726	ChEMBL_ID
CHEMBL719	ChEMBL_ID
D016712	MESH_DESCRIPTOR_UI
DB00410	DRUGBANK_ID
10916	IUPHAR_LIGAND_ID
5276	INN_ID
D0GX863OA5	UNII
446596	PUBCHEM_CID
221128	RXNORM
198973	MMSL
47751	MMSL
5138	MMSL
5139	MMSL
720	MMSL
002802	NDDF
005869	NDDF
387397004	SNOMEDCT_US
441528009	SNOMEDCT_US
71453003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0352	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
BACTROBAN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-028	CREAM	20 mg	TOPICAL	NDA	22 sections
MUPIROCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-158	OINTMENT	20 mg	TOPICAL	ANDA	16 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-055	CREAM	20 mg	TOPICAL	ANDA	28 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0112	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-188	OINTMENT	20 mg	TOPICAL	ANDA	19 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	21922-029	CREAM	2 g	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-137	OINTMENT	20 mg	TOPICAL	ANDA	19 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-229	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
CENTANY	HUMAN PRESCRIPTION DRUG LABEL	1	43538-300	OINTMENT	20 mg	TOPICAL	NDA	26 sections
Centany AT	HUMAN PRESCRIPTION DRUG LABEL	1	43538-310	OINTMENT	20 mg	TOPICAL	NDA	26 sections
MUPIROCIN	HUMAN PRESCRIPTION DRUG LABEL	1	45802-018	CREAM	20 mg	TOPICAL	ANDA	25 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45802-112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45802-112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45865-722	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	49999-644	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	49999-644	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1587	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4349	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4397	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50268-568	OINTMENT	20 mg	TOPICAL	ANDA	25 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0025	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0180	OINTMENT	20 mg	TOPICAL	ANDA	22 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1312	OINTMENT	20 mg	TOPICAL	ANDA	25 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1370	CREAM	20 mg	TOPICAL	ANDA	28 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	52959-743	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9850	OINTMENT	20 mg	TOPICAL	ANDA	22 sections